公开(公告)号：US20240301076A1

公开(公告)日：2024-09-12

申请号：US18666190

申请日：2024-05-16

Applicant: Cephalon LLC

Inventor： Doris Shim Siew Chen ,  Lynn Dorothy Poulton ,  Adam Clarke ,  David Jose Simon Laine ,  Matthew Pollard ,  Bridget Ann Cooksey ,  Anthony Doyle ,  Jason William Gill

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61P11/00 ,  G01N33/53

CPC classification number: C07K16/2866 ,  A61P11/00 ,  A61K39/395 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/53

Abstract: Disclosed herein are human antibody molecules that immunospecifically bind to human CXCR2. The disclosed human antibody molecules are potent and selective antagonists of CXCR2 functions and prevent the recruitment of neutrophils into tissues without strongly depleting circulating neutrophil numbers. Pharmaceutical compositions, nucleic acid molecules, vectors, cells, and uses of the disclosed antibodies are also provided.

公开(公告)号：US12018084B2

公开(公告)日：2024-06-25

申请号：US17718622

申请日：2022-04-12

Applicant: Cephalon LLC

Inventor： Doris Shim Siew Chen ,  Lynn Dorothy Poulton ,  Adam Clarke ,  David Jose Simon Laine ,  Matthew Pollard ,  Bridget Ann Cooksey ,  Anthony Doyle ,  Jason William Gill

IPC: A61K39/395 ,  A61P11/00 ,  C07K16/28 ,  G01N33/53 ,  A61K39/00

CPC classification number: C07K16/2866 ,  A61P11/00 ,  A61K39/395 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/53

Abstract: Disclosed herein are human antibody molecules that immunospecifically bind to human CXCR2. The disclosed human antibody molecules are potent and selective antagonists of CXCR2 functions and prevent the recruitment of neutrophils into tissues without strongly depleting circulating neutrophil numbers. Pharmaceutical compositions, nucleic acid molecules, vectors, cells, and uses of the disclosed antibodies are also provided.

公开(公告)号：US20250122291A1

公开(公告)日：2025-04-17

申请号：US18913217

申请日：2024-10-11

Applicant: Cephalon LLC

Inventor： Teresa Domagala ,  David Rickards ,  Jennifer Renee Stratton ,  Kimberly Danielle Mackenzie ,  Eric C. Beattie ,  Adam Clarke

IPC: C07K16/28 ,  A61K39/00 ,  A61P25/02

Abstract: Disclosed herein are anti-TrkA antibodies, or antigen-binding fragments thereof, and uses of the antibodies or fragments thereof.

公开(公告)号：US11725052B2

公开(公告)日：2023-08-15

申请号：US17405275

申请日：2021-08-18

Applicant: Cephalon LLC

Inventor： Anna Mikaela Bracken ,  Adam Clarke ,  Bridget A. Cooksey ,  Anthony Gerard Doyle ,  Mark Terence Liddament ,  Matthew Pollard ,  Lynn Poulton ,  Anna Maria Matilda Quigley ,  Julia Rozenfeld ,  Marta Szabat

IPC: A61K39/00 ,  A61K39/395 ,  G01N33/53 ,  C12P21/06 ,  C12N5/02 ,  C12N15/00 ,  C07K16/00 ,  C07K16/46 ,  C07H21/04 ,  C07K16/28 ,  A61P17/10 ,  A61P29/00 ,  A61P35/04

CPC classification number: C07K16/28 ,  A61P17/10 ,  A61P29/00 ,  A61P35/04 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human PAR-2 and compositions comprising such antibodies or antigen-binding fragments thereof. In a particular aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human PAR-2 block the interaction between a PAR-2 activating ligand and an extracellular domain of PAR-2, and/or blocks PAR-2 activation by a PAR-2 activating ligand, In further aspects, the antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with increased expression of PAR-2 and/or diseases or conditions that can be alleviated by antagonizing activation of PAR-2 by a PAR-2 activating ligand (e.g., airway diseases, skin diseases, cancer, orofacial granulomatosis, inflammatory conditions, and pain associated with various diseases or conditions).